Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
Drugs targeting myostatin reverse muscle wasting in animal models, but have limited efficacy in patients. The authors show that the myostatin pathway is downregulated in patients, possibly explaining the poor outcome of anti-myostatin approaches, and that it can be reactivated by correcting disease-...
| Главные авторы: | , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Статья |
| Язык: | English |
| Опубликовано: |
Nature Portfolio
2017-11-01
|
| Серии: | Nature Communications |
| Online-ссылка: | https://doi.org/10.1038/s41467-017-01486-4 |